SAN DIEGO - Organovo Holdings, Inc. (NASDAQ:ONVO), a biotechnology company specializing in novel treatments for inflammatory bowel disease and other conditions, announced significant findings from a Phase 2 study of its drug FXR314. The results were presented at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD) that took place from November 15-19.
Dr. Eric Lawitz, from the Texas Liver Institute and the University of Texas Health San Antonio, delivered the findings on Sunday during the conference. The study focused on the drug's effects on patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), a liver condition. The 16-week trial was randomized, placebo-controlled, and multi-centered, involving 214 patients who were given either 3 mg or 6 mg doses of FXR314, or a placebo.
The study showed a statistically significant reduction in liver fat content for the groups receiving FXR314 compared to the placebo group. Specifically, patients experienced a liver fat reduction with a least-squares (LS) mean percent reduction at the end of treatment of 22.8% for the 3 mg dose and 17.5% for the 6 mg dose, against 6.1% for the placebo. Additionally, 29.2% and 32.2% of patients in the 3 mg and 6 mg dosage groups, respectively, saw over a 30% reduction in fat fraction, as measured by MRI.
FXR314 was found to be safe and well-tolerated, with most treatment-emergent adverse events being mild to moderate. The safety profile of FXR314 also indicated significantly lower pruritus rates, a common side effect of FXR agonists. Furthermore, no significant increases in LDL-C levels were observed.
Dr. Lawitz expressed optimism about the drug's potential, noting the treatment's liver fat reduction capabilities and its safety profile. The study's findings support further evaluation of FXR314 for treating MASH due to its unique profile and specificity.
Organovo's proprietary technology involves developing drugs tested in three-dimensional human tissues that mimic human tissue composition and function. The company's lead molecule, FXR314, is also being considered for application in metabolic liver disease and oncology.
This report is based on a press release statement from Organovo Holdings, Inc. Investors are reminded that forward-looking statements are subject to risks and uncertainties, as disclosed in the company's filings with the SEC.
InvestingPro Insights
Despite the promising results from Organovo Holdings' Phase 2 study of FXR314, the company's financial health presents a complex picture. According to InvestingPro data, Organovo's market capitalization stands at a modest $5.24 million, reflecting the early-stage nature of its biotechnology ventures.
InvestingPro Tips highlight that Organovo holds more cash than debt on its balance sheet, which could provide some financial flexibility as it advances its drug development programs. However, the company is quickly burning through cash, a common challenge for biotech firms in the research and development phase.
The company's revenue for the last twelve months as of Q2 2025 was just $0.1 million, with a concerning revenue growth rate of -72.01%. This aligns with the InvestingPro Tip indicating that Organovo is not profitable over the last twelve months, underscoring the speculative nature of investing in early-stage biotech companies.
Investors should note that Organovo's stock has faced significant headwinds, with a one-year price total return of -73.34% as of the latest data. This performance is consistent with the InvestingPro Tip stating that the stock has fared poorly over the last month and has fallen significantly over the last year.
For those interested in a deeper analysis, InvestingPro offers 12 additional tips for Organovo, providing a more comprehensive view of the company's financial situation and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.